• Mobius Therapeutics, LLC, announced that it has received from the Centers for Medicare & Medicaid Services (CMS) an outpatient payment indicator for reimbursement of Mitosol (mitomycin for solution) Kit for Ophthalmic Use.

    The company received Outpatient Prospective Payment System Payment Indicator "K2" for the code J7315 reimbursing for the Mitosol Kit. Reimbursement to compounded medication is excluded under this code.

    "In light of the ongoing concerns related to the sterility and quality assurance of compounded medications, this will give providers and patients peace of mind, knowing that the precision, safety, and convenience of Mitosol is also the wise economic choice," said Ed Timm, President of Mobius Therapeutics.